Second-Line Therapy for Elderly Patients with Non-small Cell Lung Cancer Who Failed Previous Chemotherapy Is as Effective as for Younger Patients

It was found that second-line or thereafter therapies for patients with non-small cell lung cancer (NSCLC) who failed previous chemotherapy yielded a modest survival benefit. However, whether elderly patients (≥70 years) benefit and are as suitable for salvage therapy as nonelderly patients (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thoracic oncology 2010-03, Vol.5 (3), p.376-379
Hauptverfasser:	Wu, Chieh-Hung, Fan, Wen-Chien, Chen, Yuh-Min, Chou, Kun-Ta, Shih, Jen-Fu, Tsai, Chun-Ming, Lee, Yu-Chin, Perng, Ruery-Perng
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - pathology Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - pathology Elderly Female Gefitinib Humans Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Middle Aged Neoplasm Staging Non-small cell lung cancer Prognosis Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Retrospective Studies Salvage Therapy Survival Rate Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	It was found that second-line or thereafter therapies for patients with non-small cell lung cancer (NSCLC) who failed previous chemotherapy yielded a modest survival benefit. However, whether elderly patients (≥70 years) benefit and are as suitable for salvage therapy as nonelderly patients (
ISSN:	1556-0864 1556-1380
DOI:	10.1097/JTO.0b013e3181cee2d4